Table 1

Baseline characteristics of healthy controls (HC) and spinal cord injury (SCI) patients

HCCCSiSCIcSCIp Value
n6741013
Gender (n females, %)38 (57)1 (25)3 (30)5 (38)0.254
Age (years)35 (28–42)49 (39–62)33 (22–43)32 (22–45)0.117
Level of injury0.999
Cervicalna4911
Thoracicna012
Injury mechanism (n, %)*na0.034
Motor vehicle accident1 (25)7 (70)10 (77)
Work accident1 (25)1 (10)
Sport injury2 (20)3 (23)
Fall2 (50)
ASIA Score (n,%)†na<0.0001
A12 (92)
B1 (8)
C2 (50)7 (70)
D2 (50)3 (30)
Motor scorena59 (18–83)45 (23–63)16 (9–29)0.053
Pinprick score‡na65 (22–94)81 (51–94)24 (19–32)0.020
Light touch§na73 (25–106)76 (37–97)24 (19–32)0.028
Delay to surgery (hours)na15 (10–200)12 (8–16)18 (12–22)¶0.285
Treatment (n,%)na0.499
Placebo1 (25)5 (50)7 (53.8)
Low dose**1 (25)3 (30)1 (7.7)
High dose2 (50)2 (20)5 (38.5)
  • Medians and IQR are shown, if not specified otherwise.

  • *More motor vehicle accidents in cSCI versus CCS (p<0.05).

  • †higher ASIA score in cSCI versus iSCI (p<0.001) and CCS (p<0.01).

  • ‡lower pinprick score in cSCI versus iSCI (p<0.05).

  • §lower light touch score in cSCI versus CCS (p<0.05).

  • ¶One patient without surgical decompression.

  • **Low dose: 200 mg twice daily; high dose: 800 mg loading dose tapered to 200 mg twice daily.

  • ASIA, American Spinal Injury Association standardised neurological examination; CCS, central cord syndrome; cSCI, motor-complete spinal cord injury; iSCI, motor-incomplete spinal cord injury; na, not applicable.